Dapagliflozin improved symptoms and physical limitations in patients with heart failure (HF) with preserved ejection fraction, according to results from the PRESERVED-HF trial.
Dapagliflozin eases symptoms and physical limitations among patients who have heart failure with preserved ejection fraction (HFpEF) within a relatively short time period.
Treatment with dapagliflozin improves the symptoms of patients with heart failure with preserved ejection fraction (HFpEF), according to new findings presented at the Heart Failure Society of America's Annual Scientific Meeting.
The SGLT2 inhibitor dapagliflozin scored a clear win in a randomized, controlled trial with more than 300 U.S. patients with heart failure with preserved ejection fraction (HFpEF).
Dr. Andrew Schlachter, pulmonologist and critical care physician at Saint Luke's, talks to FOX4 about Duvernay-Tardif returning to play with the Chiefs this season.
Saint Luke’s Health System Critical Access Region Chief Executive Officer Steve Schieber answered questions during a conference call on September 1st regarding the COVID-19 vaccination mandate announced by Saint Luke’s.
